Cell Culture and Virus Vector Core

细胞培养和病毒载体核心

基本信息

项目摘要

The mission of the Cell and Virus Vector Core Laboratory is to provide cell culture-related reagents and services that meet the needs of the Cancer Center research community and support high-quality research. The CWCL stocks media and reagents and prepares custom media formulations under strict quality-control procedures, at considerable savings for Cancer Center members. Other functions of the CCWL are to maintain a repository of frozen cell lines, virus stocks and virus vectors, to establish primary cell cultures, to expand tissue culture cells for large-scale experiments, and to perform mycoplasma assays. The CWCL also serves the scientific needs of the Cancer Center researchers by offering customized assistance for research projects. Since its inception in 1978, the CWCL has worked in close collaboration with investigators to develop tools and methods essential for their research. Some recent examples include methods to produce vaccinia virus and simian virus 5 that are used for experimental prostate and brain cancer treatments by CCCWFU investigators. In addition, ELISA tests and plaque assays to evaluate novel compounds for anti-hepatitis virus and HIV-1 activity, cytotoxicity assays to evaluate prospective anticancer agents, modified focus formation assays to uncover novel oncogenes, and the expression of recombinant proteins using retroviral vectors or tetracycline-inducible vectors have been developed. The ready availability of reagents and cells combined with the expertise of the CVVCL staff greatly speeds up the development and implementation of new research projects and reduces the need to hire and train new personnel. Thus, the CWCL is an essential component of the Cancer Center that maximizes the productivity of investigators and enables them to stay competitive for obtaining extramural grant support. Usage of the Cell and Virus Vector Core Laboratory has increased by -20% yearly since 2001 without changes in personnel number. Over 60% of the CVVCL charge-back income in fiscal year 2005 came from Cancer Center members with active peer-reviewed research on approved cancer-related projects. Currently, user charge backs account for -78% of the core's total operating budget, and the CCSG and our Institution both support -11% of the total operating budget. To meet the growing needs of the Cancer Center investigators, we anticipate it will become necessary to hire additional personnel by year 2007.
细胞和病毒载体核心实验室的使命是提供细胞培养相关试剂, 满足癌症中心研究社区需求并支持高质量研究的服务。 CWCL储备培养基和试剂,并在严格的质量控制下制备定制培养基配方 为癌症中心的会员节省了可观的费用。CCWL的其他功能包括 维持冷冻细胞系、病毒原液和病毒载体的储存库,以建立原代细胞培养物, 扩大组织培养细胞进行大规模实验,并进行支原体检测。CWCL 还通过提供定制的援助,为癌症中心研究人员的科学需求服务, 研究项目。自1978年成立以来,该公司一直与 研究人员开发研究所需的工具和方法。最近的一些例子包括 生产用于实验前列腺和脑的牛痘病毒和猿猴病毒5的方法 CCCWFU研究人员的癌症治疗。此外,ELISA试验和空斑试验可用于评估新的 用于抗肝炎病毒和HIV-1活性的化合物,用于评价预期抗癌活性的细胞毒性试验 药物、发现新癌基因的改良病灶形成试验以及重组 已经开发了使用逆转录病毒载体或四环素诱导型载体的蛋白质。可轻易获得 与CVVCL工作人员的专业知识相结合,大大加快了开发速度 新的研究项目的实施和减少需要雇用和培训新的人员。因此,在本发明中, CWCL是癌症中心的一个重要组成部分,可以最大限度地提高研究人员的工作效率 并使他们能够保持竞争力,以获得校外赠款支持。 自2001年以来,细胞和病毒载体核心实验室的使用率每年增加20%, 人员数量的变化。2005财政年度CVVCL费用返还收入的60%以上来自 癌症中心成员,对已批准的癌症相关项目进行积极的同行评审研究。目前, 用户收费占核心业务总预算的78%,CCSG和我们的机构 两者都支持总业务预算的-11%。满足癌症中心日益增长的需求 调查员,我们预计到2007年将有必要雇用更多的人员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ISABELLE M BERQUIN其他文献

ISABELLE M BERQUIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ISABELLE M BERQUIN', 18)}}的其他基金

Cell Culture and Virus Vector Core
细胞培养和病毒载体核心
  • 批准号:
    7529744
  • 财政年份:
    2007
  • 资助金额:
    $ 8.92万
  • 项目类别:
Role of YB-1 in EGFR regulation and breast cancer
YB-1 在 EGFR 调节和乳腺癌中的作用
  • 批准号:
    7267699
  • 财政年份:
    2006
  • 资助金额:
    $ 8.92万
  • 项目类别:
Role of YB-1 in EGFR regulation and breast cancer
YB-1 在 EGFR 调节和乳腺癌中的作用
  • 批准号:
    7458833
  • 财政年份:
    2006
  • 资助金额:
    $ 8.92万
  • 项目类别:
Role of YB-1 in EGFR regulation and breast cancer
YB-1 在 EGFR 调节和乳腺癌中的作用
  • 批准号:
    7148827
  • 财政年份:
    2006
  • 资助金额:
    $ 8.92万
  • 项目类别:
Role of YB-1 in EGFR regulation and breast cancer
YB-1 在 EGFR 调节和乳腺癌中的作用
  • 批准号:
    7629718
  • 财政年份:
    2006
  • 资助金额:
    $ 8.92万
  • 项目类别:
Role of YB-1 in EGFR regulation and breast cancer
YB-1 在 EGFR 调节和乳腺癌中的作用
  • 批准号:
    7858424
  • 财政年份:
    2006
  • 资助金额:
    $ 8.92万
  • 项目类别:
Cell Culture and Virus Vector Core
细胞培养和病毒载体核心
  • 批准号:
    8555580
  • 财政年份:
    1997
  • 资助金额:
    $ 8.92万
  • 项目类别:
Cell Culture and Virus Vector Core
细胞培养和病毒载体核心
  • 批准号:
    9000111
  • 财政年份:
    1997
  • 资助金额:
    $ 8.92万
  • 项目类别:
Cell Culture and Virus Vector Core
细胞培养和病毒载体核心
  • 批准号:
    8714174
  • 财政年份:
  • 资助金额:
    $ 8.92万
  • 项目类别:
Cell Culture and Virus Vector Core
细胞培养和病毒载体核心
  • 批准号:
    8567726
  • 财政年份:
  • 资助金额:
    $ 8.92万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 8.92万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 8.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 8.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 8.92万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 8.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了